The Risks of Breast Augmentation: A Guide for First-Timers

By Your Health Magazine Contributor

Your Health Magazine Contributor

. https://YourHealthMagazine.net

More Women's Health & Beauty Articles

The Risks of Breast Augmentation: A Guide for First-Timers

Somewhere in your consult, a nurse will slide a patient decision checklist across the desk and ask you to initial each page. The FDA has required that document since October 27, 2021, and it exists because patients kept walking out of consults without the one sentence that reframes everything else. Breast implants are not lifetime devices. Not “may eventually need attention.” Not lifetime devices, printed in a box, in the labeling, agreed to in writing by you and your surgeon.

Most first-timers arrive having researched the cancer risk, which is real and genuinely rare. Almost none of them have priced the second surgery, which is neither.

Nobody Hands You a Quote for the Operation After This One

Look at the 10-year follow-up on Allergan’s Natrelle 410, one of the better documented historical implant cohorts. Of 492 primary augmentation patients, 29.7% had at least one reoperation inside 10 years, and 16.8% had an implant taken out and replaced. Capsular contracture, malposition, rupture, a change of mind about size, tissue that sagged while the implant stayed put: any of them sends you back.

In that particular Natrelle 410 cohort, that works out to roughly three in ten patients undergoing at least one reoperation over a decade.

Now price it. ASPS puts the average surgeon’s fee for augmentation at $4,875, and that number excludes anesthesia, the facility, and in many practices the implants themselves. Whatever you were quoted on the phone, the surgeon’s fee is a fraction of it. Here’s the part that does the damage, straight from the ASPS cost page: most health insurance plans won’t cover cosmetic augmentation, its complications, or revision surgery, and some policies go further and exclude coverage for breast disease in patients who have implants.

The broader point is that reoperation is not rare over the life of an implant, and patients should plan for the possibility of paying for another procedure later.

Plenty of women get 20 years out of one set and never think about any of this. That outcome is common and it isn’t a sales line. But the honest way to plan is to assume you’ve bought a maintenance schedule, not an object.

The Complication You’re Most Likely to Actually Meet

Your body walls off every implant in a capsule of scar tissue. That part is normal and happens to everyone. Capsular contracture is when the capsule tightens around the implant and squeezes, so the breast goes firm, rides high, distorts, and eventually hurts. In that same Natrelle 410 cohort, 9.2% hit Baker grade III or IV within 10 years. If you want to learn more about it, click here.

Surgical technique and implant characteristics may affect that risk. A 2025 meta-analysis in Aesthetic Surgery Journal Open Forum pooling 24 studies found lower odds of capsular contracture with subpectoral versus prepectoral placement (OR 0.35) and higher odds with smooth versus textured implants (OR 2.80). However, a newer 2026 meta-analysis found that the apparent texture-related difference was no longer statistically significant after accounting for implant plane and excluding overlapping or historical cohorts. The evidence therefore supports surgical plane as an important factor, while the independent effect of implant texture remains less certain.

The texture question also has to be considered alongside lymphoma risk. Allergan pulled its Biocell textured implants off the world market in 2019 over BIA-ALCL concerns, so a first-timer in the US today is very likely getting a smooth device. That shift reduced exposure to the textured surfaces most strongly associated with BIA-ALCL, even as researchers continue studying how implant characteristics and surgical technique affect other complications.

The Cancer Risk

BIA-ALCL is a lymphoma of the capsule, not breast cancer, and it remains predominantly associated with textured-surface implants. An ASPS page last updated in October 2020 listed 885 unique cases worldwide and 36 deaths; FDA surveillance data subsequently reported 1,380 BIA-ALCL medical device reports as of June 30, 2024.

The device-level numbers are where it gets useful. Lifetime risk with Allergan Biocell ran somewhere between 1 in 2,207 and 1 in 3,345. With Mentor’s Siltex texture, 1 in 86,029. Both were “textured implants” in the same sentence of every article written at the time, and they differed by a factor of roughly 26 to 39.

The overwhelming majority of reported cases have involved textured implants or an incomplete prior implant history. In the FDA’s June 2024 data, 40 reports listed a smooth implant at diagnosis; most involved prior textured implants or an unknown prior implant history, while one report listed a smooth implant with no known textured implant history.

Treated properly, usually with complete removal of the capsule, 93% of patients are disease-free at three years.

BIA-SCC, flagged by the FDA in 2022 and updated in 2023, is a separate and rarer thing. It shows up in the capsule too, but across both surfaces and both fills, and reported cases in the FDA’s review were diagnosed approximately 7 to 42 years after initial implant placement when timing information was available. If you’re 26 and choosing a device this month, it is another long-term risk worth understanding even though the reported cases are rare and have generally occurred years after implantation.

Silent Rupture Earns Its Name

Silicone gel implants can fail without a symptom you’d notice. That’s why the FDA recommends your first ultrasound or MRI at 5 to 6 years post-op, then another every 2 to 3 years for as long as you have them. Get implants at 28 and the first scan lands around 34. Stretch every follow-up to the full three years and you’ve still had eight of them by 55. Keep them to two and it’s eleven.

Insurance coverage for surveillance imaging varies by plan and medical indication, so some patients may face out-of-pocket costs.

Fatigue & Brain Fog

FDA-required breast implant labeling and the patient decision checklist address reported systemic symptoms including fatigue, memory problems, joint pain, rash, and brain fog. FDA’s own language is that these “may be associated” with implants, that the mechanism is poorly understood, and that some patients improve after removal. That’s a weaker claim than the explant forums make and a much stronger one than your surgeon’s brochure implies. Unexplained isn’t the same as imaginary, and a surgeon who waves the whole category off is telling you something about how they’ll handle you if it happens.

Ask your surgeon what the 10-year plan looks like in dollars. Not the quote for Tuesday, the quote for the whole thing: the scans, the revision odds, the price of explant with capsulectomy if you want out at 40, and who pays when a complication shows up in year seven. A good surgeon has those numbers ready and will give them to you slightly reluctantly, because they’re unglamorous. If what comes back instead is reassurance and a financing brochure, you’ve learned the most useful thing you’ll learn all week, and it had nothing to do with implants.